Clinical trial
A Prospective, Multi-cohort, Exploratory Phase II Study of Trilaciclib Combined With Standard Chemotherapy in The Adjuvant Treatment of Hormone Receptor (HR) Negative Breast Cancer
NCT05978648 is registered in ClinicalTrials.gov with wang shusen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-cohort, Exploratory Phase II Study of Trilaciclib Combined With Standard Chemotherapy in The Adjuvant Treatment of Hormone Receptor (HR) Negative Breast Cancer
- Lead sponsor
- wang shusen
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 20, 2023
- Completion date
- December 31, 2027
- Enrollment
- 116 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.